Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Two-layered immune escape in AML is overcome by Fcγ receptor activation and inhibition of PGE2 signaling in NK cells.
Rothfuß C, Baumann T, Donakonda S, Brauchle B, Marcinek A, Urban C, Mergner J, Pedde AM, Hirschberger A, Krupka C, Neumann AS, Hänel G, Merten C, Öllinger R, Hecker JS, Bauer T, Schmid CR, Götze KS, Altomonte J, Bücklein VL, Jacobs R, Rad R, Dawid C, Simeoni L, Schraven B, Pichlmair A, Subklewe M, Knolle PA, Böttcher JP, Höchst B. Rothfuß C, et al. Among authors: bucklein vl. Blood. 2025 Jan 21:blood.2024025706. doi: 10.1182/blood.2024025706. Online ahead of print. Blood. 2025. PMID: 39840945
Prognostic significance of immune reconstitution following CD19 CAR T-cell therapy for relapsed/refractory B-cell lymphoma.
Stock S, Bücklein VL, Blumenberg V, Magno G, Emhardt AJ, Holzem AME, Cordas Dos Santos DM, Schmidt C, Grießhammer S, Frölich L, Kobold S, von Bergwelt-Baildon M, Rejeski K, Subklewe M. Stock S, et al. Among authors: bucklein vl. Hemasphere. 2025 Jan 13;9(1):e70062. doi: 10.1002/hem3.70062. eCollection 2025 Jan. Hemasphere. 2025. PMID: 39807276 Free PMC article.
Safety and Efficacy of Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma in a Multinational Real-World Study.
Shumilov E, Wurm-Kuczera R, Kerkhoff A, Wang M, Melchardt T, Holtick U, Bacher U, Staber PB, Mazzeo P, Leng C, Böckle D, Hölscher AS, Kauer J, Rotter N, Vucinic V, Rudzki JD, Nachbaur D, Bücklein VL, Schnetzke U, Krämer I, Wille K, Hasse A, von Tresckow B, Hänel M, Koenecke C, Velazquez GF, Viardot A, Schmid C, Thurner L, Wolf D, Subklewe M, Dreyling M, Dreger P, Dietrich S, Keller U, Jaeger U, Greil R, Pabst T, Lenz G, Chapuy B. Shumilov E, et al. Among authors: bucklein vl. Blood Adv. 2024 Dec 11:bloodadvances.2024014903. doi: 10.1182/bloodadvances.2024014903. Online ahead of print. Blood Adv. 2024. PMID: 39661985
Evolution of T-cell fitness through AML progression: enhanced bispecific T-cell engager-mediated function of bone marrow T cells at remission compared to initial diagnosis and relapse.
Kazerani M, Marcinek A, Philipp N, Brauchle B, Taylor JJ, Moreno HD, Terrasi A, Tast B, Rohrbacher L, Wang Y, Warm M, Emhardt AJ, Magno G, Spiekermann K, Herold T, Straub T, Theurich S, Schotta G, Kischel R, Bücklein VL, Subklewe M. Kazerani M, et al. Among authors: bucklein vl. Leukemia. 2024 Oct;38(10):2270-2275. doi: 10.1038/s41375-024-02387-4. Epub 2024 Aug 22. Leukemia. 2024. PMID: 39174782 Free PMC article. No abstract available.
Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality.
Rejeski K, Wang Y, Hansen DK, Iacoboni G, Bachy E, Bansal R, Penack O, Müller F, Bethge W, Munoz J, Mohty R, Bücklein VL, Barba P, Locke FL, Lin Y, Jain MD, Subklewe M. Rejeski K, et al. Among authors: bucklein vl. Blood Adv. 2024 Apr 23;8(8):1857-1868. doi: 10.1182/bloodadvances.2023011767. Blood Adv. 2024. PMID: 38181508 Free PMC article.
Functional connectivity MRI provides an imaging correlate for chimeric antigen receptor T-cell-associated neurotoxicity.
Stoecklein S, Wunderlich S, Papazov B, Winkelmann M, Kunz WG, Mueller K, Ernst K, Stoecklein VM, Blumenberg V, Karschnia P, Bücklein VL, Rejeski K, Schmidt C, von Bergwelt-Baildon M, Tonn JC, Ricke J, Liu H, Remi J, Subklewe M, von Baumgarten L, Schoeberl F. Stoecklein S, et al. Among authors: bucklein vl. Neurooncol Adv. 2023 Oct 24;5(1):vdad135. doi: 10.1093/noajnl/vdad135. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 38024243 Free PMC article.
Predictive value of pre-infusion tumor growth rate for the occurrence and severity of CRS and ICANS in lymphoma under CAR T-cell therapy.
Winkelmann M, Blumenberg V, Rejeski K, Quell C, Bücklein VL, Ingenerf M, Unterrainer M, Schmidt C, Dekorsy FJ, Bartenstein P, Ricke J, von Bergwelt-Baildon M, Subklewe M, Kunz WG. Winkelmann M, et al. Among authors: bucklein vl. Ann Hematol. 2024 Jan;103(1):259-268. doi: 10.1007/s00277-023-05507-9. Epub 2023 Oct 20. Ann Hematol. 2024. PMID: 37861736
Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R/R DLBCL.
Blumenberg V, Busch G, Baumann S, Jitschin R, Iacoboni G, Gallur L, Iraola-Truchuelo J, Hoster E, Winkelmann M, Hellwig K, Schmidt C, Frölich L, Tast B, Hildebrand F, Rejeski K, Dekorsy F, Schmidkonz C, Bäuerle T, Kunz WG, Mougiakakos D, Müller F, von Bergwelt-Baildon M, Barba P, Bücklein VL, Mackensen A, Völkl S, Subklewe M. Blumenberg V, et al. Among authors: bucklein vl. Blood Adv. 2023 Nov 28;7(22):6844-6849. doi: 10.1182/bloodadvances.2023010364. Blood Adv. 2023. PMID: 37748131 Free PMC article.
Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion.
Rejeski K, Perez A, Iacoboni G, Blumenberg V, Bücklein VL, Völkl S, Penack O, Albanyan O, Stock S, Müller F, Karschnia P, Petrera A, Reid K, Faramand R, Davila ML, Modi K, Dean EA, Bachmeier C, von Bergwelt-Baildon M, Locke FL, Bethge W, Bullinger L, Mackensen A, Barba P, Jain MD, Subklewe M. Rejeski K, et al. Among authors: bucklein vl. Sci Adv. 2023 Sep 22;9(38):eadg3919. doi: 10.1126/sciadv.adg3919. Epub 2023 Sep 22. Sci Adv. 2023. PMID: 37738350 Free PMC article.
The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL.
Rejeski K, Wang Y, Albanyan O, Munoz J, Sesques P, Iacoboni G, Lopez-Corral L, Ries I, Bücklein VL, Mohty R, Dreyling M, Baluch A, Shah B, Locke FL, Hess G, Barba P, Bachy E, Lin Y, Subklewe M, Jain MD. Rejeski K, et al. Among authors: bucklein vl. Am J Hematol. 2023 Nov;98(11):1699-1710. doi: 10.1002/ajh.27056. Epub 2023 Aug 16. Am J Hematol. 2023. PMID: 37584447 Free PMC article.
29 results